reports
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty P...
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard)MacroGenics’ cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that it has entered into a royalty purchase agreement with Sagard i...
- Jonathan Moreland
TDOC TELADOC HEALTH INC.
VFF VILLAGE FARMS INTERNATIONAL IN
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
VLA ARBOR METALS
DLHC DALEIGH HOLDINGS CORP
IMNM IMMUNOME
TSHA TAYSHA GENE THERAPIES
AFBI AFFINITY BANCSHARES
EVM INC.
SDHY EATON VANCE INSD CALIF MUN BD FD
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthc...
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. A webcast of the above presentation may be accessed under ...
- David Nierengarten
- Dennis Pak
- Martin Fan
Perma Fix Environmental Services Inc: 1 director
A director at Perma Fix Environmental Services Inc sold 16,634 shares at 10.920USD and the significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
BLDR BUILDERS FIRSTSOURCE INC.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
PINS PINTEREST INC. CLASS A
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
UFPI UFP INDUSTRIES INC.
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
NUVB NUVATION BIO INC (A)
RBLX ROBLOX
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
TCRX TSCAN THERAPEUTICS INC
APP APPLOVIN CORP
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
NUVL NUVALENT INC
ARTV ARTIVA BIOTHERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
BCAX BICARA THERAPEUTICS INC.
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
NVCR NOVOCURE LTD.
FATE FATE THERAPEUTICS INC
ISR ISORAY
REPL REPLIMUNE GROUP
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
TCRX TSCAN THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
NUVL NUVALENT INC
ARTV ARTIVA BIOTHERAPEUTICS INC
BCAX BICARA THERAPEUTICS INC.
Compass Diversified Takes Action to Improve its Financial Position in ...
Compass Diversified Takes Action to Improve its Financial Position in Response to Investigation into Lugano Holding, Inc. Entered into Forbearance Agreement with Lender Group Reduced Management Fees Suspended Quarterly Distribution on Common Shares Received Notice of Late Filing from NYSE WESTPORT, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI”) today provided an update on steps it is taking to enhance liquidity and reduce costs in the wake of its announcement that it is investigating, and has preliminarily identified irregularities in, the financing,...
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
NVCR NOVOCURE LTD.
FATE FATE THERAPEUTICS INC
MRSN MERSANA THERAPEUTICS
ISR ISORAY
RCUS ARCUS BIOSCIENCES
REPL REPLIMUNE GROUP
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ACET ADICET BIO INC
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
FHTX FOGHORN THERAPEUTICS
GLUE MONTE ROSA THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
NUVL NUVALENT INC
ARTV ARTIVA BIOTHERAPEUTICS INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
BCAX BICARA THERAPEUTICS INC.
MacroGenics Provides Update on Corporate Progress and First Quarter 20...
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025 Advancement in portfolio of innovative ADC product candidates, including MGC026, MGC028 and MGC030 Cash, cash equivalents and marketable securities of $154.1 million as of March 31, 2025 ROCKVILLE, Md., May 13, 2025 (GLOBE NEWSWIRE...
- Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
OFC CORPORATE OFFICE PROPERTIES TRUST
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GPRO GOPRO INC. CLASS A
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BZH BEAZER HOMES USA INC.
AXTI AXT INC.
DHI D.R. HORTON INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
BLDR BUILDERS FIRSTSOURCE INC.
TMHC TAYLOR MORRISON HOME CORPORATION
ARGX ARGENX ADS
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
SMCI SUPER MICRO COMPUTER
BDTX INC.
LSEA BLACK DIAMOND THERAPEUTICS
IMNM LANDSEA HOMES CORP (A)
STX IMMUNOME
GFS SEAGATE TECHNOLOGY HLDGS PLC
MLTX GLOBALFOUNDRIES INC
GETY MOONLAKE IMMUNOTHERAPEUTICS
DNTH GETTY IMAGES HOLDINGS INC
MXL-US DIANTHUS THERAPEUTICS INC
SDHC-US MAXLINEAR
INC.
SMITH DOUGLAS HOMES CORP.
Moody's Ratings places Compass Group's ratings under review for downgr...
Moody's Ratings (Moody's) placed Compass Group Diversified Holdings LLC's (Compass) ratings under review for downgrade, including the Ba3 Corporate Family Rating (CFR); Ba3-PD Probability of Default Rating (PDR), and the B1 rating on the company's senior unsecured notes. Previously, the outlook was ...
- David Nierengarten
- Dennis Pak
- Martin Fan
Perma-Fix Reports Q1 2025 Results and Highlights Momentum in Hanford a...
Perma-Fix Reports Q1 2025 Results and Highlights Momentum in Hanford and PFAS Programs Improved gross margins and rising backlog driven by increased waste receipts Strategic investments expected to position the Company for stronger performance in the second half of 2025 ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the first quarter ended March 31, 2025. "Our first quarter results reflect the impact of several transitional headwinds," said Mark Duff, Pr...
Compass Diversified Discloses Non-Reliance on Financial Statements for...
Compass Diversified Discloses Non-Reliance on Financial Statements for Fiscal 2024 Amid an Ongoing Internal Investigation into its Subsidiary, Lugano Holding, Inc. The Company Intends to Delay Quarterly Earnings and Filing of 2025 Q1 Form 10-Q WESTPORT, Conn., May 07, 2025 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI”) today disclosed non-reliance on its financial statements for fiscal 2024 amid an ongoing internal investigation into its subsidiary, Lugano Holding, Inc. It also announced that it intends to delay the filing of its first quarter 2025 Form 10-Q. The Audit...
MacroGenics Announces Date of First Quarter 2025 Financial Results
MacroGenics Announces Date of First Quarter 2025 Financial Results ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025. The Company will not be hosting a conference call to discuss its financial results or corporate progress for the quarter ended Marc...
Perma-Fix Schedules First Quarter 2025 Business Update Conference Call
Perma-Fix Schedules First Quarter 2025 Business Update Conference Call ATLANTA, May 05, 2025 (GLOBE NEWSWIRE) -- Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced it will host a conference call at 10:00 AM Eastern Time on Thursday, May 8, 2025. A webcast of the call may be accessed at or in the investor section of the Company’s website at . The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or for international callers, and by entering access code: 146674. The conference call will be led by Mark J....
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics to Participate in Upcoming Investor Conference ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month: The Citizens Life Sciences Conference (New York). Members of MacroGenics’ management team will participate in a fireside chat on Thursday, May 8, 2025, at 10:3...
- Wedbush Research
TPH TRI POINTE HOMES INC.
NVCR NOVOCURE LTD.
GLPI GAMING AND LEISURE PROPERTIES INC.
CNK CINEMARK HOLDINGS INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
ROKU ROKU INC. CLASS A
VICI VICI PROPERTIES INC
EPRT ESSENTIAL PROPERTIES REALTY TRUST
YMAB Y-MABS THERAPEUTICS
PEAK HEALTHPEAK PROPERTIES INC.
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
FUBO FUBOTV
IMNM IMMUNOME
VOR VOR BIOPHARMA
TNGX TANGO THERAPEUTICS
NUVL INC
NUVALENT INC
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.